JAC Advance Access originally published online on March 5, 2008
Journal of Antimicrobial Chemotherapy 2008 61(5):973-975; doi:10.1093/jac/dkn060
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leading article |
The involvement of HIV-1 RNAse H in resistance to nucleoside analogues
1 AP-HP, Groupe Hospitalier Bichat-Claude Bernard, Service de Virologie, Paris F-75018, France 2 Université Denis Diderot-Paris 7, Paris, France 3 AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Virologie, Paris F-75013, France 4 UPMC Univ Paris 06, EA 2387, Paris F-75005, France
* Correspondence address. Service de Virologie, Hôpital Pitié-Salpêtrière, 83 Boulevard de l'Hôpital, 75013 Paris, France. Tel: +33-142177401; Fax: +33-142177411; E-mail: anne-genevieve.marcelin{at}psl.aphp.fr
Some recent studies have underlined the role of the entire reverse transcriptase (RT) and in particular its carboxy-terminal domain from amino acid 427 to amino acid 560 [the ribonuclease H (RNAse H) domain] in resistance to nucleoside RT inhibitors (NRTIs). RNAse H is implicated in catalysing the degradation of the RNA strand during conversion of the viral genome into double-stranded DNA. It has been shown, by site-directed mutagenesis, that amino acid substitutions in the RNAse H domain could affect the binding enzyme/substrate, resulting in a decrease in the RNAse H activity. For example, mutations at positions 478, 539 and 549 led to a slowing down in the degradation of the RNA strand. In vitro, the mutations H539N and D549N decreased the frequency of RT template-switching and, thereby, increased the time for excision of incorporated NRTIs, and thus enhanced NRTI resistance. It has been confirmed in vivo that mutations at position 558 were statistically associated with a number of thymidine analogue mutations in a study including 144 HIV-1 patients, suggesting that it could be an accessory mutation that could reinforce NRTI resistance. This article highlights evidence that mutations in RNAse H can enhance NRTI resistance, suggesting that phenotypic and genotypic analyses of clinical samples including the entire HIV-1 RT and in particular the RNAse H domain are now required to better characterize the in vivo role of the RNAse H mutations on susceptibility and response to NRTIs in HIV-1-infected patients.
Keywords: reverse transcriptase , NRTIs , susceptibility
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. A. Delviks-Frankenberry, G. N. Nikolenko, F. Maldarelli, S. Hase, Y. Takebe, and V. K. Pathak Subtype-Specific Differences in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Connection Subdomain of CRF01_AE Are Associated with Higher Levels of Resistance to 3'-Azido-3'-Deoxythymidine J. Virol., September 1, 2009; 83(17): 8502 - 8513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Garriga, M. J. Perez-Elias, R. Delgado, L. Ruiz, L. Perez-Alvarez, T. Pumarola, A. Lopez-Lirola, J. Gonzalez-Garcia, L. Menendez-Arias, and on behalf of the Spanish Group for the Study of An HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations J. Antimicrob. Chemother., August 1, 2009; 64(2): 251 - 258. [Abstract] [Full Text] [PDF]
|
|